The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

ProMetic Life Sciences Inc

TSX: PLI
Delayed quote

$2.23

Today's change-0.08 -3.46%
Updated July 6 4:00 PM EDT. Delayed by at least 15 minutes.
 

ProMetic Life Sciences Inc

TSX: PLI
Delayed quote

$2.23

Today's change-0.08 -3.46%
Updated July 6 4:00 PM EDT. Delayed by at least 15 minutes.

ProMetic Life Sciences Inc crosses below 20-day moving average

ProMetic Life Sciences Inc closed sharply lower Monday, dropping $0.08 or 3.46% to $2.23 and crossing below its 20-day moving average. Over the last five days, shares have gained 10.40% and 16.75% year to date. Shares have outperformed the S&P TSX by 127.08% during the last year.

Key company metrics

  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield--
  • Trailing EPS-$0.02
Updated July 6 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-47.99%

Although this company's net profit margin is negative, it is above the industry average and implies that ProMetic Life Sciences Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.60%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2015Q4/2014Q3/2014Q2/2014
Fiscal Quarter Endvalues in $ millions unless otherwise notedMar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014
Revenue21124
Total other revenue--------
Total revenue21124
Gross profit1812
Total cost of revenue1212
Total operating expense2012126
Selling / general / administrative3533
Research & development1012810
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)6-70-8
Other operating expenses, total--------
Operating income-18-1-9-2
Interest income (expense), net non-operating---1----
Gain (loss) on sale of assets------0
Other--------
Income before tax-215-2123
Income after tax-208-2123
Income tax, total-1-400
Net income-199-1924
Total adjustments to net income--------
Net income before extra. items-199-1924
Minority interest2111
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-199-1924
Inc. avail. to common incl. extra. items-199-1924
Diluted net income-199-1924
Dilution adjustment--000
Diluted weighted average shares552727531577
Diluted EPS excluding extraordinary itemsvalue per share-0.030.01-0.040.04
Dividends per sharevalue per share0.00--0.000.00
Diluted normalized EPSvalue per share-0.030.01-0.040.03